Alli hits Europe, beefing up GSK's consumer line

GlaxoSmithKline launched its nonprescription weight-loss drug alli in European pharmacies, boosting its line-up of consumer products in the region. Glaxo is eyeing its OTC meds for growth at a time when prescription drug sales are slowing down. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.